1Rosalind Franklin University of Medicine and Science, College of Pharmacy, North
2Department of Pharmacy, Rush University Medical Center, Chicago, USA
*Corresponding Author: Eris Tollkuci, Rosalind Franklin University of Medicine and Science, College of Pharmacy and Department of Pharmacy, Rush University Medical Center, Chicago, USA.
Received: December 26, 2019; Published: January 09, 2020
With advances in cancer prevention, diagnosis and treatment, patient outcomes and survival rates are increasing. Although healthcare providers’ primary focus remains improving overall survival, supportive care methods focusing on fertility preservation are also significant. Survey results from cancer survivors have revealed that 30-40% of the time providers did not discuss fertility preservation prior to initiation of cancer treatment and about half of the time patients self-inquired about fertility preservation.
According to the World Cancer Research Fund about 8.5 million women are diagnosed with cancer each year. Many of these women will undergo a wide variety of therapies such as surgery, radiation therapy, chemotherapy, immunotherapy and targeted therapy. The risk of treatment-related infertility varies greatly depending on the treatment modality utilized as well as patient-specific characteristics (i.e. age, sex).
Citation: Eris Tollkuci. “Fertility Preservation: An Important Consideration Prior to Malignancy Treatment”. Acta Scientific Women's Health 2.2 (2020): 35.
Copyright: © 2020 Eris Tollkuci. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.